Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints
Author: Benzinga Newsdesk | April 22, 2024 08:03am